Enstilar® - the First Combination Foam Spray for Psoriasis Launches in the UK - Seite 3

About Enstilar^® 

Enstilar^® (calcipotriol/betamethasone dipropionate) is a topical, alcohol-free, foam spray treatment for all severities of plaque psoriasis in patients who are 18 years or older.^[1] It is designed to provide patients with a convenient treatment option that can be easily applied.^[2] In clinical trials, the foam spray was generally well-tolerated^[2],[3] and provided relief from psoriasis symptoms, including itch.^[4] Patients treated with the new product in clinical trials experienced significant improvements in symptoms within the first week, and more than half achieved treatment success after four weeks.^[4]

About Psoriasis  

Psoriasis is a chronic, inflammatory skin disease, which is frequently accompanied by multiple physical and/or psychological comorbidities (the presence of one or more additional diseases), such as psoriatic arthritis, diabetes, cardiovascular disease and depression.^[10]

Psoriasis is estimated to affect up to 3% of the population of the UK.^[11] 80% of patients are affected by plaque psoriasis - the most common type of psoriasis.^[9]

Topical treatments can be used as first-line therapies for the majority of patients living with psoriasis.^[12]

About LEO Pharma  

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases.

LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. The UK/IE affiliate is headquartered in Hurley, Berkshire.

For more information about LEO Pharma UK/IE, visit http://www.leo-pharma.co.uk.

References 

1. Enstilar® SmPC; UK. Available at: http://www.medicines.org.uk Last Accessed June 2016 

2. Koo J, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. Journal of Dermatological Treatment 2015; 1471-1753 

3. Taraska V, et al. A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris. Journal of Cutaneous Medicine and Surgery 2015; 1-8